These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8614841)

  • 41. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy.
    Newman EA; Cimmino VM; Sabel MS; Diehl KM; Frey KA; Chang AE; Newman LA
    Ann Surg Oncol; 2006 Jan; 13(1):52-7. PubMed ID: 16372155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast conservation therapy in patients with mammographically undetected breast cancer.
    Samuels JR; Haffty BG; Lee CH; Fischer DB
    Radiology; 1992 Nov; 185(2):425-7. PubMed ID: 1329142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.
    Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ
    Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Axillary recurrence in DCIs: is axillary lymphadenectomy warranted?
    Trisal V; Qian D; Wagman LD
    Am Surg; 2004 Oct; 70(10):876-80. PubMed ID: 15529841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Axillary lymph node dissection: does it have a role in primary breast cancer?
    Pack MS; Thomas RS
    Am Surg; 1996 Feb; 62(2):159-61. PubMed ID: 8554194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2011 Dec; 18 Suppl 3():S339-42. PubMed ID: 19777181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The surgical management of early breast cancer.
    Young AE
    Int J Clin Pract; 2001 Nov; 55(9):603-8. PubMed ID: 11770357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies.
    Jenkinson AD; Al-Mufti RA; Mohsen Y; Berry MJ; Wells C; Carpenter R
    Eur J Surg Oncol; 2001 Feb; 27(1):21-5. PubMed ID: 11237487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors for local recurrence in breast conservation therapy: residual cancers after lumpectomy.
    Fukutomi T; Yamamoto H; Nanasawa T; Itabashi M; Hirota T
    Surg Today; 1993; 23(5):402-6. PubMed ID: 8324333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The conservative treatment of early breast cancer. The 1st Annual Wendell G. Scott Memorial Lecture.
    Hayward J
    Cancer; 1974 Feb; 33(2):593-9. PubMed ID: 4812775
    [No Abstract]   [Full Text] [Related]  

  • 55. How to perform adequate local excision of mammographically detected lesions.
    Cady B
    Surg Oncol Clin N Am; 1997 Apr; 6(2):315-34. PubMed ID: 9115498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new topographic approach to the spread of breast cancer: the grid method.
    Noël P; Gerard JP; Mayer M; Bailly C; Blondet R; Bobin JY; Colon J; Deglise P
    Cancer; 1977 Aug; 40(2):924-7. PubMed ID: 890673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimally invasive surgery in breast cancer treatment.
    Singletary SE
    Biomed Pharmacother; 2001 Nov; 55(9-10):510-4. PubMed ID: 11769957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mammographic surveillance after breast conservation therapy.
    Dershaw DD; Lee CH; Morris EA
    Radiology; 2013 Feb; 266(2):685. PubMed ID: 23362098
    [No Abstract]   [Full Text] [Related]  

  • 59. Minimally invasive techniques in breast cancer treatment.
    Singletary SE
    Semin Surg Oncol; 2001; 20(3):246-50. PubMed ID: 11523110
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ablative approaches to the minimally invasive treatment of breast cancer.
    Agnese DM; Burak WE
    Cancer J; 2005; 11(1):77-82. PubMed ID: 15831228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.